Capstone Investment Advisors
RVMD icon

Capstone Investment Advisors’s Revolution Medicines RVMD Stock Holding History

Capstone Investment Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Buy
+7,200
New +$1.05M ﹤0.01% 850
2025
Q4 		– Sell
-5,534
Closed -$258K – 1988
2025
Q3 		$258K Buy
+5,534
New +$217K ﹤0.01% 1708

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Capstone Investment Advisors's RVMD Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in Revolution Medicines (RVMD) in Q2 2026: 7,200 shares worth $1.35M. The stake represents ﹤0.01% of the portfolio and ranks #850 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in RVMD as recently as Q3 2025.

Capstone Investment Advisors first reported a position in RVMD in Q3 2025 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Capstone Investment Advisors held 7,200 shares of Revolution Medicines worth $1.35M as of Q2 2026.
  • Revolution Medicines was a new Capstone Investment Advisors position in Q2 2026.
  • Revolution Medicines made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #850 holding.
  • Capstone Investment Advisors first reported a position in Revolution Medicines in Q3 2025 and has held it in 2 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.